Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Neoplasms 1Muscle Invasive Bladder Cancer 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 6sargramostim 5Psychiatric Rehabilitation 5Early Intervention, Educational 5Magnetic Resonance Spectroscopy 4Gemcitabine 4Cyclophosphamide 4palbociclib 3Trastuzumab 3Therapeutics 3Standard of Care 3Radiotherapy 3Oxaliplatin 3Methods 3Irinotecan 3Interferon-alpha 3Fluorouracil 3Fluorodeoxyglucose F18 3Erlotinib Hydrochloride 3Docetaxel 3Bortezomib 3temsirolimus 2motexafin gadolinium 2entinostat 2cemiplimab 2cediranib 2Specimen Handling 2Radiosurgery 2Practice Guidelines as Topic 2Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × AZD 6244 × Genitourinary × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡